EGFR and neoplasm: Osimertinib is the latest generation targeted drug that acts on the EGFR signaling pathway and competitively binds to EGFR to inhibit complex kinase activation, thereby blocking the EGFR signaling pathway, which consequently inhibits tumor cell proliferation and metastasis and promotes tumor cell apoptosis [17].